1. Adverse events of injected CGRP inhibitors

   News item 02 July 2022 Pages: 1 - 1

2. Artri King product recalled due to presence of undeclared drugs

   News item 02 July 2022 Pages: 2 - 2

3. Dexmedetomidine increases risk of death in ICU patients

   News item 02 July 2022 Pages: 3 - 3

4. Empagliflozin-related tubulointerstitial nephritis

   News item 02 July 2022 Pages: 4 - 4

5. Loperamide-related risk of acute pancreatitis

   News item 02 July 2022 Pages: 5 - 5

6. Unauthorised health products in Canada pose health risks

   News item 02 July 2022 Pages: 6 - 6

7. ADRs common in patients with drug-resistant TB

   Clinical study 02 July 2022 Pages: 7 - 7

8. Antipsychotics associated with drug-induced liver injury

   Clinical study 02 July 2022 Pages: 8 - 8

9. CGRP receptor antagonists better tolerated than triptans

   Clinical study 02 July 2022 Pages: 9 - 9

10. Immune checkpoint inhibitors: risk of myocardial/pericardial disorders

    Clinical study 02 July 2022 Pages: 10 - 10

11. Registry data on AEs related to medicinal products

    Clinical study 02 July 2022 Pages: 11 - 11

12. Signal detection of COVID-19 vaccine-related AEs

    Clinical study 02 July 2022 Pages: 12 - 12

13. Other adverse reaction research

    News item 02 July 2022 Pages: 13 - 13

14. Agaricus blazei Murill-extract/gemcitabine/paclitaxel

    Case report 02 July 2022 Pages: 14 - 14

15. Abemaciclib/anastrozole/palbociclib

    Case report 02 July 2022 Pages: 15 - 15

16. Abemaciclib/letrozole

    Case report 02 July 2022 Pages: 16 - 16

17. Acalabrutinib

    Case report 02 July 2022 Pages: 17 - 17

18. Acetazolamide/bevacizumab

    Case report 02 July 2022 Pages: 18 - 18

19. Acetylcysteine/amitriptyline/ascorbic-acid

    Case report 02 July 2022 Pages: 19 - 19

20. Aciclovir/immune-globulin/pembrolizumab

    Case report 02 July 2022 Pages: 20 - 20

21. Aciclovir/prednisolone/pregabalin

    Case report 02 July 2022 Pages: 21 - 21

22. Adalimumab

    Case report 02 July 2022 Pages: 22 - 22

23. Adalimumab/azathioprine

    Case report 02 July 2022 Pages: 23 - 23

24. Adrenergic receptor agonists/iohexol/methotrexate

    Case report 02 July 2022 Pages: 24 - 24

25. Afatinib/toripalimab

    Case report 02 July 2022 Pages: 25 - 25

26. Aflibercept

    Case report 02 July 2022 Pages: 26 - 26

27. Aflibercept/bevacizumab/infliximab

    Case report 02 July 2022 Pages: 27 - 27

28. Aflibercept/brolucizumab/ranibizumab

    Case report 02 July 2022 Pages: 28 - 28

29. Albendazole

    Case report 02 July 2022 Pages: 29 - 29

30. Alectinib/lorlatinib

    Case report 02 July 2022 Pages: 30 - 30

31. Alemtuzumab/rituximab

    Case report 02 July 2022 Pages: 31 - 31

32. Alprazolam/amfetamine

    Case report 02 July 2022 Pages: 32 - 32

33. Alteplase

    Case report 02 July 2022 Pages: 33 - 33

34. Alteplase/dornase alfa

    Case report 02 July 2022 Pages: 34 - 34

35. Aluminium-hydroxide/magnesium-hydroxide

    Case report 02 July 2022 Pages: 35 - 35

36. Amikacin/ciprofloxacin/linezolid

    Case report 02 July 2022 Pages: 36 - 36

37. Amiodarone

    Case report 02 July 2022 Pages: 37 - 37

38. Amiodarone

    Case report 02 July 2022 Pages: 38 - 38

39. Amlodipine/lacosamide/levetiracetam interaction

    Case report 02 July 2022 Pages: 39 - 39

40. Amoxicillin

    Case report 02 July 2022 Pages: 40 - 40

41. Amphotericin-b-liposomal

    Case report 02 July 2022 Pages: 41 - 41

42. Amphotericin-B-liposomal

    Case report 02 July 2022 Pages: 42 - 42

43. Amphotericin-B-liposomal/potassium-iodide

    Case report 02 July 2022 Pages: 43 - 43

44. Amphotericin-B/dexamethasone/prednisolone

    Case report 02 July 2022 Pages: 44 - 44

45. Anakinra/canakinumab

    Case report 02 July 2022 Pages: 45 - 45

46. Analgesics

    Case report 02 July 2022 Pages: 46 - 46

47. Anti-inflammatories

    Case report 02 July 2022 Pages: 47 - 47

48. Anti-inflammatories

    Case report 02 July 2022 Pages: 48 - 48

49. Antibacterials

    Case report 02 July 2022 Pages: 49 - 49

50. Antibacterials/allopurinol/sulfasalazine

    Case report 02 July 2022 Pages: 50 - 50